Choppa P C, Vojdani A, Tagle C, Andrin R, Magtoto L
Immunosciences Lab Incorporated Beverly Hills, CA, USA.
Mol Cell Probes. 1998 Oct;12(5):301-8. doi: 10.1006/mcpr.1998.0186.
A multiplex polymerase chain reaction (PCR) was initially developed to detect the presence of mycoplasma genus DNA sequences in cell cultures and to differentiate between three human pathogenic mycoplasma species simultaneously. The assay in turn, proved to be a useful tool for the detection of mycoplasma infection in human DNA samples. One set of oligonucleotide primers which are specific for a highly conserved region among all members of the genus mycoplasma along with three other primer sets which are specific for Mycoplasma fermentans, Mycoplasma hominis andMycoplasma penetrans species were used in this assay. The sensitivity of detection was determined by infecting peripheral blood mononuclear cells (PBMC) of healthy individuals with known bacterial copy numbers from each species, extracting the DNA, and subjecting 1 microgram of DNA from each sample to 40 cycles of amplification. By using agarose gel electrophoresis the detection level was determined to be 7, 7, 9 and 15 mycoplasma cells per microgram of human genomic DNA for M. genus,M. fermentans, M. hominis and M. penetrans, respectively. The assay was applied to DNA extracted from the PBMCs of individuals suffering from chronic fatigue syndrome (CFS) (n=100) as determined by the Center for Disease Control (CDC) criteria, and compared to healthy individuals (n=100). The percentage of M. genus infection was found to be 52% in CFS patients and only 15% in healthy individuals. Mycoplasma fermentans, M. hominis andM. penetrans were detected in 32, 9 and 6% of the CFS patients while they were detected in 8, 3 and 2% of the healthy control subjects, respectively. This assay provides a rapid and cost efficient procedure to screen either cell cultures or clinical samples for the presence of three potentially pathogenic species of mycoplasma with a high level of sensitivity and specificity.
多重聚合酶链反应(PCR)最初是为检测细胞培养物中支原体属DNA序列的存在,并同时区分三种人类致病支原体物种而开发的。反过来,该检测方法被证明是检测人类DNA样本中支原体感染的有用工具。在该检测中使用了一组针对支原体属所有成员中高度保守区域的寡核苷酸引物,以及另外三组分别针对发酵支原体、人型支原体和穿透支原体物种的引物。通过用已知每种物种细菌拷贝数感染健康个体的外周血单核细胞(PBMC)、提取DNA,并对每个样本的1微克DNA进行40个循环的扩增来确定检测灵敏度。通过琼脂糖凝胶电泳,确定每微克人类基因组DNA中支原体属、发酵支原体、人型支原体和穿透支原体的检测水平分别为7、7、9和15个支原体细胞。该检测方法应用于从符合疾病控制中心(CDC)标准确定的慢性疲劳综合征(CFS)患者(n = 100)的PBMC中提取的DNA,并与健康个体(n = 100)进行比较。发现CFS患者中支原体属感染的百分比为52%,而健康个体中仅为15%。在32%、9%和6%的CFS患者中检测到发酵支原体、人型支原体和穿透支原体,而在健康对照受试者中分别为8%、3%和2%。该检测方法提供了一种快速且经济高效的程序,用于筛选细胞培养物或临床样本中三种潜在致病支原体物种的存在,具有高度的灵敏度和特异性。